Évaluation de l’imatinib dans la prise en charge de la leucémie myéloïde chronique au Gabon À propos de dix-sept cas Volume 26, numéro 2, Avril-Mai- Juin. REVUE MEDICALE DE LIEGE. Cliquer ICI pour déclencher le téléchargement de l’article. COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE. Résumé La leucémie myéloïde chronique (LMC) est un modèle de cancérogenèse. Son pronostic a été exceptionnellement amélioré grâce.
|Published (Last):||20 February 2014|
|PDF File Size:||7.72 Mb|
|ePub File Size:||12.17 Mb|
|Price:||Free* [*Free Regsitration Required]|
Chronic myeloid leukaemia in South African blacks. Access to the full text of this article requires a subscription. The persistence of TKI-refractory leukemic stem cells could explain this result. An experience from eastern India.
Top of the page – Article Outline. Outline Masquer le plan.
RMLG – ACCES A L’ARTICLE :COMMENT JE TRAITE LA LEUCEMIE MYELOIDE CHRONIQUE (LMC).
Access to the PDF text. Chronic myeloid leukaemia at the Kenyatta National Hospital, Nairobi. N Engl J Med. Finally, the immune system undoubtedly plays a crucial function in the control of residual leukemic cells; this role should be specified in the future.
Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.
Chronic myeloid leukaemia in central Chfonique.
East Afr Med J. S Af Med J.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties. You can move this window by clicking on the headline. Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Molecular biology of bcr-abl1-positive CML. Acellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia.
Leucémie myéloïde chronique (LMC)
Les inhibiteurs des kinases. As per the Law relating to information storage and personal integrity, you have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal data. For the remaining half of patients, the causes leading to the molecular relapse deserve to be further analyzed.
Hematologic and cytogenetic response to Imatinib mesylate in chronic myelogenous leukemia. Personal information regarding our website’s visitors, including their identity, is confidential. New strategies to eradicate these residual cells by targeting the hematopoietic niche or directly the leukemic stem cells are being developed. Access to the text HTML. Chronic myeloid leukemia advances in biology and new approaches to treatment.
If you want to subscribe to this journal, see our rates You can purchase this item in Pay Per View: If you are a subscriber, please sign in ‘My Account’ at the top right of the screen. Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries.
Leucémie myéloïde chronique (LMC) · Groupe québécois de recherche en LMC-NMP
New technologies digital PCR, high-throughput sequencing or NGS were developed to improve the performances of existing methods. Leucejie trials have validated TKI discontinuation strategies in patients with sustained deep molecular response. Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.
Journal page Archives Contents list. A retrospective study of leukemia epidemiology in Northern Tunisia. Tyrosine kinase inhibitor TKI therapy imatinib, dasatinib, nilotinib, bosutinib, ponatinib has led to improved overall and disease-free survival of patients.
Clinical and pronognostic features mheloide Nigerians with chronic myeloid leukemia. Contact Help Who are we? Indian J Hematol Blood Transfus. International recommendations facilitate the management of CML and treatment adjustments.
The Glivec international patient assistance programme: